<DOC>
	<DOCNO>NCT01743950</DOCNO>
	<brief_summary>To determine efficacy Pulse Reduced Dose Rate ( PRDR ) radiation give 27 fraction 5.5 week concurrent bevacizumab follow adjuvant bevacizumab time progression patient recurrent high grade glioma ( grade III grade IV ) . Patients place 1 4 group base histologic diagnosis prior exposure bevacizumab .</brief_summary>
	<brief_title>A Phase II Study Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically confirm diagnose grade WHO grade III IV glioma Recurrent disease base combination clinical , image histologic confirmation Must previously receive radiation temozolomide treat glioma Bevacizumab naive patient must &gt; 6months post completion initial radiation therapy Bevacizumab expose patient must &gt; 3months post completion initial radiation therapy Age must &gt; 18years , KPS must great 60 Hematology , chemistry urinalysis must meet protocol specify criterion Pregnant breastfeeding May full dose anticoagulation therapy , Low molecular weight heparin ok Uncontrolled hypertension ( &gt; 140/90mmHg ) Prior malignancy unless treat &gt; 1 year prior study without treatment disease free 1 yr active second malignancy unless nonmelanoma skin cancer cervical cancer situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>anaplastic glioma</keyword>
</DOC>